Lilly/Incyte's JAK inhibitor needs RA Phase III to compare with Pfizer's tofacitinib
This article was originally published in Scrip
Executive Summary
Lilly and Incyte have reported positive 12-week data from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available Janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).